Navigation Links
New Migraine Drug Might Be Safer for Some
Date:4/22/2010

And an old standby might help prevent headache from starting up, report finds

THURSDAY, April 22 (HealthDay News) -- A drug under development could help patients with migraines, while an existing epilepsy drug might prevent the headaches from developing in the first place, new research suggests.

The report, published April 21 in The Lancet, examines the migraine drug telcagepant, which is not yet available, and topiramate (Topamax), an epilepsy drug sometimes used to treat migraines when they occur.

Telcagepant relieves pain in a similar way to the drugs known as triptans that are used to treat migraine. But it doesn't cause blood vessels to constrict, a troublesome side effect for people with heart disease, the report says.

Triptans often don't work, and they can cause side effects like dizziness, throat tightness, chest discomfort and numbness. For its part, telcagepant can cause side effects like dry mouth, dizziness, nausea and drowsiness.

Telcagepant is a "promising compound," writing the study authors, but add that further investigation is needed.

Also in the report, the authors say topiramate is showing promise as a preventive treatment for migraines. It's cost-effective and typically leads to weight loss instead of weight gain, they report.

The authors write that the drug "should especially be considered for adult patients who are overweight, or have epilepsy or a contraindication to beta blockers. It is generally safe and well-tolerated. Thus topiramate is an important drug for difficult cases."

The report authors are Dr. Lars Edvinsson of University Hospital in Lund, Sweden, and Dr. Mattias Linde of the Norwegian University of Science and Technology in Trondheim, Norway.

More information

The U.S. National Library of Medicine has more about migraine headaches.



-- Randy Dotinga



SOURCE: The Lancet, news release, April 21, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Uninsured get poor care for migraine: Harvard study
2. Finding Good Migraine Care a Headache for the Uninsured
3. New Hope for Migraine Patients
4. Chronic Migraines Take a Greater Toll
5. Migraine More Common in Women with MS
6. Migraine Tied to Raised Multiple Sclerosis Risk
7. Botox May Prevent Some Migraines
8. Migraine Linked to Increased Heart Attack Risk
9. Migraine, Depression May Have Genetic Link
10. Study explains why light worsens migraine headaches
11. Why Light Hurts During Migraines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: